BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare I&I: Psoriatic Arthritis (PsA) Market Spotlight

September 09, 2020

Psoriatic arthritis (PsA) is a chronic, inflammatory autoimmune condition that occurs in some psoriasis patients. It causes inflammation that can trigger pain, swelling, stiffness, and fatigue in the joints. About 30% of individuals with psoriasis develop PsA, and if left untreated, the disease can lead to permanent tissue and joint damage. The exact cause of PsA is unknown; however, it is believed that genetic, immunologic, and environmental factors play an important role in the pathogenesis of the disease. Familial studies provide evidence of a strong genetic basis in PsA, particularly with regard to the human leukocyte antigen (HLA) region. These genes are involved in identifying the invading bacteria and viruses. People with HLA gene variations are at an increased risk of developing the disease, although other environmental and genetic risk factors also contribute to the development of PsA. Environmental factors including strep throat infection, an injury, or extreme stress can lead to an overactive immune system, particularly in individuals who are genetically at a higher risk of developing the disease. The immune system, particularly lymphocytes, plays an important role in the pathogenesis of PsA. This is supported by the presence of activated natural killer cells and CD8+ T cells in the synovium, as well as by how the disease responds to immunomodulatory treatment.

This Datamonitor Healthcare report contains a Market Spotlight module.

Indications Covered: Psoriatic Arthritis (PA)
Back to the top Back to the top